[Statistical analysis of variations in total cholesterol, HDL, HDL2, HDL3, LDL-cholesterol, VLDL-triglycerides, apo-A and apo-B lipoproteins in dyslipidemias during antilipemic therapy].
In our study, bezafibrate in short-acting formula and long-acting formula, administered to hyperlipidaemic patients, resulted in a significant lowering of atherogenic lipids and lipoproteins (chol.-T, LDL and VLDL-chol., apolipoprotein B and VDLD-TR), and a marked increase in the levels of HDL, HDL2, HDL3-chol. and apolipoprotein A with a protective action as regards vascular atherosclerotic damage. The long-acting formula showed a greater effectiveness.
D000328:Adult; D000368:Aged; D001053:Apolipoproteins / Q000097:blood; D001629:Bezafibrate / Q000008:administration & dosage / Q000627:therapeutic use*; D002784:Cholesterol / Q000097:blood; D002986:Clinical Trials as Topic; D003692:Delayed-Action Preparations; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy*; D008074:Lipoproteins / Q000097:blood; D008297:Male; D008875:Middle Aged; D014280:Triglycerides / Q000097:blood
D001053:Apolipoproteins; D003692:Delayed-Action Preparations; D008074:Lipoproteins; D014280:Triglycerides; D002784:Cholesterol; D001629:Bezafibrate
Analisi statistica delle variazioni del colesterolo totale, HDL, HDL2, HDL3, LDL-colesterolo, VLDL-trigliceridi, apo-A e apo-B lipoproteine nelle dislipidemie in trattamento antilipemico.